查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1993878

mRNA疫苗和治疗市场：全球产业分析、市场规模、市场份额及按治疗方法、类型、应用、最终用户、国家和地区分類的预测——2026-2033年

mRNA Vaccines And Therapeutics Market, By Treatment Type, By Type, By Application, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 339 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2025 年，mRNA 疫苗和治疗药物市场价值将达到 29.8076 亿美元，并将在 2026 年至 2033 年期间以 30.6% 的复合年增长率增长。

mRNA疫苗和疗法是一种先进的生物技术解决方案，它利用传讯RNA）诱导细胞产生特定蛋白质，从而预防和治疗疾病。这种方法使人体免疫系统能够识别并攻击目标病原体或异常细胞。基于mRNA的平台利用遗传讯息诱导可控的蛋白质表达，从而支持针对感染疾病、癌症和其他疾病的疫苗和疗法的研发。这些解决方案具有快速开发、精准标靶化和灵活设计等优势。透过增强免疫反应并加速创新，mRNA疫苗和疗法正在推动现代医学和下一代医疗保健技术的进步。

mRNA疫苗与治疗市场－市场动态

慢性病盛行率增加

慢性病盛行率上升指的是全球罹患癌症、心血管疾病和自体免疫疾病等长期疾病的人数不断增加。人口老化、生活方式改变和环境因素等因素共同推动了这一趋势，给医疗保健系统带来了额外的负担。在mRNA疫苗和疗法领域，慢性病负担的加重正在推动利用mRNA技术靶向特定疾病路径的创新治疗方法的研发。虽然mRNA平台支援个人化标靶治疗，但慢性病盛行率的上升正在加速先进生物技术治疗方法的研发和投资。慢性病盛行率的上升正在推动临床研究和开发，并增强现代医疗保健对mRNA疫苗和疗法的需求。例如，根据经济合作暨发展组织，截至2025年11月，心血管疾病、癌症、呼吸道疾病和糖尿病等慢性病仍将是OECD成员国面临的主要健康负担。报告指出，2022年，约8.6%的成年人患有糖尿病，超过三分之一的16岁及以上人口患有长期疾病，显示慢性病负担日益加重。此外，经合组织报告称，到2024年，45岁及以上基层医疗使用者中，82%至少患有一种慢性病，52%患有两种或两种以上慢性病，这凸显了慢性病患病率的上升以及对有效长期医疗保健管理日益增长的需求。

mRNA疫苗与治疗市场－市场区隔分析：

全球mRNA疫苗和疗法市场按治疗类型、类别、应用、最终用户和地区进行细分。

根据治疗类型，市场可分为三大类：单株抗体、基因疗法和细胞疗法。单株抗体因其在标靶疾病治疗中的有效性而占据了较大的市场份额。标靶疾病疗法是指旨在识别并作用于与疾病相关的特定细胞、蛋白质或路径的治疗方法。这种方法提高了治疗的精准性，改善了临床疗效，并最大限度地减少了对健康细胞的损伤。在mRNA疫苗和治疗领域，单株抗体被广泛用于支持癌症、感染疾病和自体免疫疾病等疾病的免疫疗法。这些治疗方法透过中和有害病原体、抑制致病机制和增强免疫反应，有助于实现更有效、更先进的治疗方案。例如，根据国际药品製造商协会联合会（IFPMA）的数据，截至2025年2月，包括单株抗体在内的生物製药将使全球超过3.5亿患者受益，用于治疗癌症、糖尿病和罕见疾病。本报告也重点介绍了药物创新持续发展的趋势。 2023 年，全球推出了 69 种新的活性成分；截至 2024 年 10 月，超过 12700 种药物处于不同的临床开发阶段，反映出先进生物製药和抗体治疗方法的强劲增长。

根据类型，mRNA疫苗市场分为两大类：自扩增mRNA疫苗和传统非扩增mRNA疫苗。自扩增mRNA疫苗因其能够增强蛋白质表现并降低剂量，占据了市场的大部分份额。增强蛋白表现是指自扩增mRNA疫苗能够在细胞内复製RNA，产生更高水平的抗原并诱导更强的免疫反应。在自扩增mRNA疫苗中，这种增强的表达能够扩大免疫覆盖范围，从而可能减少加强剂的接种次数，并对新出现的病原体做出快速反应。这些优势使得自扩增mRNA疫苗在感染疾病、肿瘤和个人化医疗等领域极具应用前景，推动了mRNA疫苗技术在全球范围内的快速发展和普及。例如，根据英国药品和保健产品监管局 (MHRA) 的数据，2026 年 1 月，英国核准了自扩增 mRNA 新冠疫苗“Zapomeran (Kostaive)”，用于 18 岁及以上成年人。这标誌着自扩增 mRNA 疫苗（一种用于公共卫生应对的下一代疫苗）首次获得监管部门核准。该疫苗以 0.5 毫升的单次加强剂量接种，含有自扩增传讯RNA，旨在刺激人体产生 SARS-CoV-2 刺突蛋白，从而增强对新冠病毒的免疫力。

mRNA疫苗和治疗市场—区域洞察

mRNA疫苗和疗法市场受医疗基础设施、研发投入和技术应用差异的影响，呈现明显的区域性差异。在北美，尤其是在美国和加拿大，基于mRNA的治疗方法正在逐步普及，临床试验广泛开展，人们对个人化医疗的兴趣日益浓厚。欧洲市场呈现稳定成长态势，这得益于生物技术投资的增加、法规结构的支持以及创新疫苗平台的推出。亚太地区市场正在快速扩张，这主要得益于医疗服务可及性的提高、庞大的患者群体、政府支持的加强以及中国、印度、日本和韩国等国家本土生物技术能力的提升。相较之下，拉丁美洲和中东及非洲地区的市场份额正在不断扩大，这得益于医疗基础设施的改善、人们对mRNA疗法的认知度不断提高以及对临床研究和疫苗项目的参与度不断提高。

日本mRNA疫苗和治疗市场—国家概况

由于完善的医疗基础设施和生物技术创新的快速应用，日本mRNA疫苗和疗法市场正经历稳定成长。医疗机构和研究机构越来越多地利用mRNA疫苗和疗法来支持感染疾病预防和个人化医疗。国内外主要製药公司的积极参与，以及政府支持疫苗研发和核准的政策，持续推动市场扩张。此外，日本日益重视改善公共卫生状况和推进免疫接种计划，也进一步加速了mRNA疫苗和疗法在日本医疗和研究领域的应用。例如，根据英联邦基金会的一项调查，到2025年，日本的法定医疗保险制度将涵盖约98.3%的人口，确保在基于居住和工作地的强制性保险制度下，几乎全民都能获得住院治疗、初级和专科医疗服务以及处方药。政府制定医疗保险报销标准，并向地方政府和保险公司提供津贴，以维持医疗品质和可负担性。另一方面，根据年龄和收入的不同，每年最高自付费用为 340,000 至 2,120,000 日元（3,400 至 21,200 美元），这表明政府继续支持全面的医疗保健覆盖和经济保障政策。

目录

第一章：mRNA疫苗和治疗市场概述

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：mRNA疫苗和治疗药物的主要市场趋势

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 未来市场趋势

第四章：mRNA疫苗与治疗产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长前景展望图
  • 管理体制分析

第五章：mRNA疫苗与治疗市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：mRNA疫苗和治疗药物的市场趋势

  • mRNA疫苗和治疗药物市场份额分析，2025年
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章 mRNA疫苗与治疗市场：依治疗类型划分

  • 概述
    • 基于细分市场的市场份额分析：按治疗类型
    • 细胞疗法
    • 基因治疗
    • 单株抗体
    • 其他的

第八章 mRNA疫苗和治疗市场：按类型划分

  • 概述
    • 基于细分市场的市场份额分析：按类型
    • 常规非扩增mRNA疫苗
    • 自扩增mRNA疫苗

第九章 mRNA疫苗与治疗市场：依应用划分

  • 概述
    • 基于细分市场的市场份额分析：按应用领域
    • 自体免疫疾病
    • 癌症
    • 感染疾病
    • 其他的

第十章 mRNA疫苗与治疗市场：依最终用户划分

  • 概述
    • 基于细分市场的市场份额分析：按类型
    • 诊所
    • 医院
    • 研究机构和组织
    • 其他的

第十一章：mRNA疫苗和治疗市场：按地区划分

  • 介绍
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 主要製造商：欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 概述
    • 主要製造商：亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他亚太国家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他拉丁美洲国家
  • 中东和非洲
    • 概述
    • 主要生产商：中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他中东和非洲国家

第十二章 主要供应商分析：mRNA疫苗与治疗产业

  • 竞争基准
    • 竞争对手仪錶板
    • 竞争定位
  • 公司简介
    • AstraZeneca
    • Arcturus Therapeutics
    • BioNTech SE
    • CureVac NV
    • Daiichi Sankyo
    • Ethris
    • GlaxoSmithKline
    • Innovac Therapeutics
    • Kernal Biologics
    • Pantherna Therapeutics
    • pHion Therapeutics
    • Pfizer Inc.
    • Recode Therapeutics
    • Rejuvenation Technologies
    • RNAimmune
    • Strand Therapeutics
    • Moderna, Inc.
    • Walvax
    • Ziphius Vaccines
    • Others

第十三章：AnalystView 的全景视图

简介目录
Product Code: ANV6180

mRNA Vaccines And Therapeutics Market size was valued at US$2,980.76 Million in 2025, expanding at a CAGR of 30.6% from 2026 to 2033.

mRNA Vaccines And Therapeutics refer to a class of advanced biotechnology solutions that use messenger RNA to instruct cells to produce specific proteins for disease prevention or treatment. This approach enables the body's immune system to recognize and respond to targeted pathogens or abnormal cells. mRNA-based platforms utilize genetic instructions to trigger controlled protein production, supporting the development of vaccines and therapeutic applications for infectious diseases, cancer, and other medical conditions. These solutions offer advantages such as rapid development, precise targeting, and flexible design. By enhancing immune response and enabling faster innovation, mRNA Vaccines And Therapeutics contribute to the advancement of modern medicine and next-generation healthcare treatments.

mRNA Vaccines And Therapeutics Market- Market Dynamics

Increasing Prevalence Of Chronic Diseases

Increasing prevalence of chronic diseases refers to the growing number of individuals affected by long-term medical conditions such as cancer, cardiovascular diseases, and autoimmune disorders worldwide. This trend is driven by factors including aging populations, lifestyle changes, and environmental influences, which are placing greater pressure on healthcare systems. In the context of mRNA Vaccines And Therapeutics, the rising burden of chronic diseases is encouraging the development of innovative treatment approaches that utilize mRNA technology to target specific disease pathways. mRNA platforms support personalized targeted therapies while rising chronic disease prevalence accelerates research and investment in advanced biotechnology treatments. The increasing prevalence of chronic diseases drives clinical research and therapeutic development, strengthening the demand for mRNA Vaccines And Therapeutics in modern healthcare.For instance, in November 2025, according to the Organisation for Economic Co-operation and Development (OECD), chronic conditions such as cardiovascular diseases, cancer, respiratory diseases, and diabetes remain major health burdens across OECD countries. The report highlights that around 8.6% of the adult population was living with diabetes in 2022, and over one-third of people aged 16 and above reported having a long-standing illness, indicating a substantial and growing chronic disease burden. The OECD further notes that 82% of primary care users aged 45 and older reported at least one chronic condition in 2024, with 52% experiencing two or more conditions, emphasizing the increasing prevalence of chronic diseases and the rising need for effective long-term healthcare management.

mRNA Vaccines And Therapeutics Market- Segmentation Analysis:

The Global mRNA Vaccines And Therapeutics Market is segmented on the basis of Treatment Type, Type, Application, End User, and Region.

The market is divided into three categories based on treatment type: monoclonal antibody, gene therapy, and cell therapy. The monoclonal antibody segment accounts for a significant portion of the market due to its effectiveness in targeted disease treatment. Targeted disease treatment refers to therapeutic approaches designed to specifically identify and act on particular cells, proteins, or pathways associated with a disease. This method enhances treatment precision, improves clinical outcomes, and minimizes damage to healthy cells. In the context of mRNA Vaccines And Therapeutics, monoclonal antibodies are widely used to support immune-based therapies for conditions such as cancer, infectious diseases, and autoimmune disorders. These treatments help neutralize harmful pathogens, block disease-causing mechanisms, and strengthen immune responses, contributing to more effective and advanced therapeutic solutions. For instance, in February 2025, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), biologic medicines including monoclonal antibodies already benefit more than 350 million patients globally for the treatment of diseases such as cancer, diabetes, and rare disorders. The report also highlights the continued expansion of pharmaceutical innovation, with 69 novel active substances launched globally in 2023 and over 12,700 medicines in different phases of clinical development as of October 2024, reflecting strong growth in advanced biologic and antibody-based therapies.

The market is divided into two categories based on type: self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines. The Self-Amplifying mRNA-Based Vaccines segment accounts for a significant portion of the market due to its enhanced protein expression and dose-sparing potential. Enhanced protein expression refers to the ability of self-amplifying mRNA vaccines to replicate their RNA within cells, producing higher levels of antigen and eliciting stronger immune responses. In self-amplifying mRNA-based vaccines, this increased expression allows for broader immune coverage, potentially fewer booster doses, and faster response to emerging pathogens. These advantages make self-amplifying mRNA vaccines highly attractive for applications in infectious diseases, oncology, and personalized therapeutics, supporting the rapid growth and adoption of mRNA vaccine technologies globally. For instance, in January 2026, according to the UK Government Medicines and Healthcare Products Regulatory Agency, Zapomeran (Kostaive), a self-amplifying mRNA COVID-19 vaccine for adults aged 18 years and older in the UK, was approved, marking one of the first regulatory authorizations of an sa-mRNA vaccine and highlighting a shift toward next-generation mRNA technology in public health responses, with the vaccine administered as a single 0.5 mL booster dose containing self-amplifying messenger RNA designed to help the body make the SARS-CoV-2 spike protein and strengthen immunity against COVID-19.

mRNA Vaccines And Therapeutics Market- Geographical Insights

The mRNA Vaccines And Therapeutics Market exhibits clear regional variation, shaped by differences in healthcare infrastructure, R&D investment, and technology adoption. North America shows growing adoption of mRNA-based therapies, widespread clinical trials, and increasing focus on personalized medicine, particularly in the U.S. and Canada. Europe demonstrates consistent growth, driven by rising investments in biotechnology, supportive regulatory frameworks, and the adoption of innovative vaccine platforms. Asia Pacific is expanding rapidly, fueled by rising healthcare access, large patient populations, increasing government support, and the development of local biotechnology capabilities in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are developing their market presence, supported by improving healthcare infrastructure, growing awareness of mRNA therapeutics, and increasing participation in clinical research and vaccine programs.

Japan mRNA Vaccines And Therapeutics Market - Country Insights

The Japan mRNA Vaccines And Therapeutics market is experiencing consistent growth, driven by a well-developed healthcare infrastructure and rapid adoption of biotechnology innovations. Healthcare providers and research institutions are increasingly utilizing mRNA Vaccines And Therapeutics to prevent infectious diseases and support personalized medicine initiatives. Strong participation from leading domestic and global pharmaceutical companies, along with supportive government policies for vaccine development and approval, continues to encourage market expansion. Additionally, growing emphasis on improving public health outcomes and advancing immunization programs is further accelerating adoption across healthcare and research settings in Japan. For instance, in 2025, according to the Commonwealth Fund's organization, Japan's statutory health insurance system covers about 98.3% of the population, ensuring nearly universal access to hospital care, primary and specialty services, and prescription drugs under mandatory residence- and employment-based plans; the national government sets the health insurance fee schedule and subsidizes local governments and insurers to maintain quality and affordability, while out-of-pocket maximums range from JPY 340,000 to 2.12 million annually (USD 3,400-21,200) depending on age and income, demonstrating sustained government policy support for comprehensive healthcare coverage and financial protection.

mRNA Vaccines And Therapeutics Market- Competitive Landscape:

The mRNA Vaccines And Therapeutics Market is moderately concentrated, with several leading biotechnology and pharmaceutical companies driving competition. Key players include Pfizer Inc., Moderna, Inc., BioNTech SE, GlaxoSmithKline, Daiichi Sankyo, CureVac N.V., AstraZeneca, Ethris, Sanofi, Arcturus Therapeutics, Innovac Therapeutics, Kernal Biologics, Pantherna Therapeutics, pHion Therapeutics, Recode Therapeutics, Rejuvenation Technologies, RNAimmune, Strand Therapeutics, Walvax, and Ziphius Vaccines. These companies compete by developing innovative mRNA-based vaccines and therapeutics for infectious diseases, oncology, and personalized medicine. For example, in 2024, Moderna, Inc. advanced its mRNA vaccine platform to include self-amplifying mRNA technology, enabling enhanced protein expression, improved immune responses, and faster adaptation to emerging pathogens. The market is driven by increasing demand for effective, rapid-response vaccines and therapeutics, particularly in the context of emerging infectious diseases and cancer immunotherapy. Additionally, companies are expanding capabilities with enhanced delivery systems, multi-dose formulations, predictive immunogenicity modeling, and scalable manufacturing platforms to meet the evolving needs of healthcare systems and the growing preference for innovative, accessible, and safe mRNA-based treatments.

Recent Developments:

In 2025, Pfizer Inc. announced a collaboration with a leading biotechnology partner to develop next-generation mRNA vaccines aimed at improving immune response, expanding protection against emerging infectious diseases, and enhancing vaccine delivery efficiency. This initiative demonstrates Pfizer's commitment to leveraging cutting-edge mRNA technology to advance global health, potentially establishing a new standard in vaccine innovation. The partnership is set to utilize self-amplifying mRNA and enhanced delivery platforms, positioning Pfizer as a leader in innovative mRNA therapeutics.

In 2024, Kernal Biologics initiated a joint project with a prominent research institute to develop advanced mRNA therapeutics for oncology and personalized medicine applications. The collaboration focuses on optimizing mRNA design, delivery systems, and immunogenicity to improve patient outcomes. By integrating scalable manufacturing processes and predictive modeling, Kernal Biologics aims to strengthen its position as a key innovator in next-generation mRNA-based therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca
  • Arcturus Therapeutics
  • BioNTech SE
  • CureVac N.V.
  • Daiichi Sankyo
  • Ethris
  • GlaxoSmithKline
  • Innovac Therapeutics
  • Kernal Biologics
  • Pantherna Therapeutics
  • pHion Therapeutics
  • Pfizer Inc.
  • Recode Therapeutics
  • Rejuvenation Technologies
  • RNAimmune
  • Strand Therapeutics
  • Moderna, Inc.
  • Walvax
  • Ziphius Vaccines
  • Others

GLOBALMRNA VACCINES AND THERAPEUTICS MARKET, BY TREATMENT TYPE - MARKET ANALYSIS, 2020 - 2033

  • Cell Therapy
  • Gene Therapy
  • Monoclonal Antibody
  • Other

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY TYPE - MARKET ANALYSIS, 2020 - 2033

  • Conventional Non-Amplifying mRNA-Based Vaccines
  • Self-Amplifying mRNA-based Vaccines

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Autoimmune Diseases
  • Cancer
  • Infectious Diseases
  • Others

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Clinics
  • Hospitals
  • Research Laboratories and Organizations
  • Others

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. mRNA Vaccines And Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. mRNA Vaccines And Therapeutics Market Snippet by Treatment Type
    • 2.1.2. mRNA Vaccines And Therapeutics Market Snippet by Type
    • 2.1.3. mRNA Vaccines And Therapeutics Market Snippet by Application
    • 2.1.4. mRNA Vaccines And Therapeutics Market Snippet by End User
    • 2.1.5. mRNA Vaccines And Therapeutics Market Snippet by Country
    • 2.1.6. mRNA Vaccines And Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. mRNA Vaccines And Therapeutics Key Market Trends

  • 3.1. mRNA Vaccines And Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. mRNA Vaccines And Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. mRNA Vaccines And Therapeutics Market Opportunities
  • 3.4. mRNA Vaccines And Therapeutics Market Future Trends

4. mRNA Vaccines And Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. mRNA Vaccines And Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. mRNA Vaccines And Therapeutics Market Landscape

  • 6.1. mRNA Vaccines And Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. mRNA Vaccines And Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2025&2033 (%)
    • 7.1.2. Cell Therapy
    • 7.1.3. Gene Therapy
    • 7.1.4. Monoclonal Antibody
    • 7.1.5. Other

8. mRNA Vaccines And Therapeutics Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
    • 8.1.2. Conventional Non-Amplifying mRNA-Based Vaccines
    • 8.1.3. Self-Amplifying mRNA-based Vaccines

9. mRNA Vaccines And Therapeutics Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2025&2033 (%)
    • 9.1.2. Autoimmune Diseases
    • 9.1.3. Cancer
    • 9.1.4. Infectious Diseases
    • 9.1.5. Others

10. mRNA Vaccines And Therapeutics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
    • 10.1.2. Clinics
    • 10.1.3. Hospitals
    • 10.1.4. Research Laboratories and Organizations
    • 10.1.5. Others

11. mRNA Vaccines And Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025&2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. mRNA Vaccines And Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. mRNA Vaccines And Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. mRNA Vaccines And Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. mRNA Vaccines And Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAMMarket Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAMMarket Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAMMarket Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAMMarket Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. mRNA Vaccines And Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- mRNA Vaccines And Therapeutics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca
    • 12.2.2. Arcturus Therapeutics
    • 12.2.3. BioNTech SE
    • 12.2.4. CureVac N.V.
    • 12.2.5. Daiichi Sankyo
    • 12.2.6. Ethris
    • 12.2.7. GlaxoSmithKline
    • 12.2.8. Innovac Therapeutics
    • 12.2.9. Kernal Biologics
    • 12.2.10. Pantherna Therapeutics
    • 12.2.11. pHion Therapeutics
    • 12.2.12. Pfizer Inc.
    • 12.2.13. Recode Therapeutics
    • 12.2.14. Rejuvenation Technologies
    • 12.2.15. RNAimmune
    • 12.2.16. Strand Therapeutics
    • 12.2.17. Moderna, Inc.
    • 12.2.18. Walvax
    • 12.2.19. Ziphius Vaccines
    • 12.2.20. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us